GB1535203A - Hypolipidemic compositions and method of producing hypolipidemic activity - Google Patents

Hypolipidemic compositions and method of producing hypolipidemic activity

Info

Publication number
GB1535203A
GB1535203A GB44565/75A GB4456575A GB1535203A GB 1535203 A GB1535203 A GB 1535203A GB 44565/75 A GB44565/75 A GB 44565/75A GB 4456575 A GB4456575 A GB 4456575A GB 1535203 A GB1535203 A GB 1535203A
Authority
GB
United Kingdom
Prior art keywords
hypolipidemic
nov
dosage unit
norethindrone
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB44565/75A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline LLC
Original Assignee
SmithKline Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Corp filed Critical SmithKline Corp
Publication of GB1535203A publication Critical patent/GB1535203A/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
GB44565/75A 1974-11-27 1975-11-26 Hypolipidemic compositions and method of producing hypolipidemic activity Expired GB1535203A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US05/527,560 US3969508A (en) 1974-11-27 1974-11-27 Lowering the concentration of plasma triglycerides

Publications (1)

Publication Number Publication Date
GB1535203A true GB1535203A (en) 1978-12-13

Family

ID=24101958

Family Applications (1)

Application Number Title Priority Date Filing Date
GB44565/75A Expired GB1535203A (en) 1974-11-27 1975-11-26 Hypolipidemic compositions and method of producing hypolipidemic activity

Country Status (10)

Country Link
US (1) US3969508A (US20110158925A1-20110630-C00042.png)
AU (1) AU499316B2 (US20110158925A1-20110630-C00042.png)
BE (1) BE835823A (US20110158925A1-20110630-C00042.png)
DE (1) DE2553101A1 (US20110158925A1-20110630-C00042.png)
FR (1) FR2292470A1 (US20110158925A1-20110630-C00042.png)
GB (1) GB1535203A (US20110158925A1-20110630-C00042.png)
IL (1) IL48518A (US20110158925A1-20110630-C00042.png)
NL (1) NL7513877A (US20110158925A1-20110630-C00042.png)
PH (2) PH11295A (US20110158925A1-20110630-C00042.png)
ZA (1) ZA757439B (US20110158925A1-20110630-C00042.png)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1569404A (en) * 1977-04-22 1980-06-11 Soc D Etudes Prod Chimique (2-isopropyl-4-(2'-theonyl)-5-methyl) phenoxy acetic acid
US4089970A (en) * 1977-09-07 1978-05-16 Smithkline Corporation Method of inhibiting platelet aggregation
US4532135A (en) * 1981-02-09 1985-07-30 Edwards K David G Renoprotective treatments employing vasodilator compounds

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB760114A (en) * 1953-06-19 1956-10-31 Chimie Atomistique Improvements in and relating to compositions for lowering the cholesterol level in the blood serum
US3402198A (en) * 1965-10-20 1968-09-17 William A. Bolhofer 2-(phenoxy), 2-(phenylthio) and 2-(anilino) substituted 2-alkylideneacetic acid derivatives
GB1228236A (US20110158925A1-20110630-C00042.png) * 1968-05-20 1971-04-15
BE757001A (fr) * 1969-10-10 1971-03-16 Cerpha Derives heterocycliques d'acides phenoxy acetique et leur preparation

Also Published As

Publication number Publication date
NL7513877A (nl) 1976-05-31
FR2292470A1 (fr) 1976-06-25
PH12855A (en) 1979-09-12
ZA757439B (en) 1976-11-24
PH11295A (en) 1977-11-02
IL48518A0 (en) 1976-01-30
AU499316B2 (en) 1979-04-12
DE2553101A1 (de) 1976-08-12
BE835823A (fr) 1976-05-21
US3969508A (en) 1976-07-13
IL48518A (en) 1978-08-31
FR2292470B1 (US20110158925A1-20110630-C00042.png) 1978-11-10
AU8689475A (en) 1977-06-02

Similar Documents

Publication Publication Date Title
ATE116844T1 (de) Verschiedenartige zelluloseether enthaltende, oral verabreichbare arzneimittelformen mit gesteuerter wirkstofffreigabe.
ES8308698A1 (es) Procedimiento para preparar una composicion penetrable por la piel a base de agentes terapeuticos sistematicamente activos
IL92069A0 (en) Contraception system and method
IE34746L (en) 2-(n-allyl-n-arylamino)-imidazolines
EP0051706A1 (en) Gelatin capsule dosage unit containing triamterene
US4233316A (en) Analgesic potentiation
GB1535203A (en) Hypolipidemic compositions and method of producing hypolipidemic activity
US4233317A (en) Analgesic potentiation
US4233314A (en) Analgesic potentiation
JPS5540604A (en) Improved local topicum
CA1218307A (en) Use of clotrimazole in the treatment of herpes labialis
US3729563A (en) Method of treating movement disorders
US3197370A (en) Pyrilamine tannate compositions
GB2165750A (en) Contraceptive synergistic association
GB1152679A (en) Pharmaceutical and Veterinary Preparations
CA1080622A (en) Hypolipidemic compositions and method of producing hypolipidemic activity
GB1326528A (en) Method of contraception and compositions used therein
US4265893A (en) Diuretic compositions
CA1172566A (en) Method for producing pharmaceutical preparation
IE34501B1 (en) Improvements in or relating to new benzenesulphonamide derivatives
CA1207238A (en) Use of haloprogin in the treatment of herpes labialis
GB1424611A (en) Pharmaceutical compositions
GB1174988A (en) Novel Benzylaminoimidazoline Derivatives, the preparation thereof and Compositions containing the same
IE780526L (en) Compositions for inhibiting male fertility
JPS57179118A (en) Antitumor agent

Legal Events

Date Code Title Description
PS Patent sealed [section 19, patents act 1949]
PCNP Patent ceased through non-payment of renewal fee